Injectable terbutaline should not be used for prevention or prolonged treatment of preterm labor in pregnant women because of the potential for serious maternal heart problems and death, according to a warning issued by the U.S. Food and Drug Administration. The agency also warned that oral terbutaline should not be used for prevention or any treatment of preterm labor because of similar safety concerns and the fact that it has not been shown to be effective.
THURSDAY, Feb. 17 (HealthDay News) -- Injectable terbutaline should not be used for prevention or prolonged treatment of preterm labor in pregnant women because of the potential for serious maternal heart problems and death, according to a warning issued by the U.S. Food and Drug Administration. The agency also warned that oral terbutaline should not be used for prevention or any treatment of preterm labor because of similar safety concerns and the fact that it has not been shown to be effective.
The agency decided to require that a Boxed Warning and Contraindication be added to terbutaline drug labels after reviewing safety information from the medical literature and from post-marketing safety reports of terbutaline used for obstetrical indications.
Upon reviewing the new information, the FDA concluded that the risk of serious adverse events, such as increased heart rate, transient hyperglycemia, myocardial ischemia, and death, outweighs potential benefits to pregnant women receiving prolonged treatment with injectable terbutaline or acute or prolonged treatment with oral terbutaline.
"Although it may be clinically deemed appropriate based on the health care professional's judgment to administer terbutaline by injection in urgent and individual obstetrical situations in a hospital setting, the prolonged use of this drug to prevent recurrent preterm labor can result in maternal heart problems and death," according to the FDA safety announcement.
Related Content
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Model for predicting cesarean delivery in gestational diabetes
November 15th 2023A recent study unveils a pragmatic model, incorporating factors such as insulin requirements, preeclampsia, and maternal age, to effectively predict primary cesarean delivery risk in pregnancies complicated by gestational diabetes mellitus.
Read More
Hematocrit levels in newborns: EPP vs. DCC study reveals surprising findings
November 7th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Read More
Management of active phase of second stage labor and risk of urinary, anal incontinence
November 6th 2023In a recent study, rates of urinary and anal incontinence were similar among patients receiving instructions for moderate vs intensive pushing for the active phase of second stage labor.
Read More